Ensayos clínicos

Evolocumab

Comercialización: Repatha: Europa (EMA), EE.UU. (FDA)

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Estado: Completado - Resultados Publicados

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk

Estado: Completado - Resultados Publicados

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Estado: Completado - Resultados Publicados

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

Estado: Completado - Resultados Publicados

Trial Assessing Evolocumab (AMG 145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment

Estado: Completado

Estimation Study to Assess the Effect of Severe Renal Impairment and ESRD Hemodialysis on the PK of Evolocumab (AMG 145)

Estado: Completado - Resultados Publicados

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Estado: Completado - Activo, no reclutando

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Estado: Completado - Resultados Publicados

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy

Estado: Completado - Resultados Publicados

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Estado: Completado - Resultados Publicados

Durable Effect of PCSK9 Antibody Compared with Placebo Study

Estado: Completado - Resultados Publicados

Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Estado: Completado - Resultados Publicados

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Estado: Completado - Resultados Publicados

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Estado: Activo, no reclutando - Resultados Publicados

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Estado: Activo, no reclutando - Resultados Publicados

Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

Estado: Reclutando

Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound

Estado:  Completado - Resultados Publicados

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

Estado:  Completado - Resultados Publicados

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Estado:  Completado - Resultados Publicados

Open Label Study of Long Term Evaluation Against LDL-C Trial-2

Estado:  Activo, no reclutando - Resultados Publicados

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Estado:  Completado - Resultados Publicados

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Estado:  Completado - Resultados Publicados

Open Label Study of Long Term Evaluation Against LDL-C Trial

Estado:  Activo, no reclutando - Resultados Publicados

Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects

Estado:  Completado

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Estado:  Completado - Resultados Publicados

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Estado:   Reclutando

LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Estado: Completado - Resultados Publicados

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Estado:   Reclutando

Evolocumab Pregnancy Exposure Registry

Estado:   Reclutando

Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

Estado:   Reclutando

Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial

Estado:   Reclutando

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

Estado:   Sin reclutar

Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

Estado:   Sin reclutar

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Estado:   Reclutando

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Estado:   Reclutando

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Estado:   Activo, no reclutando

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

Estado:   Reclutando

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Estado:   Reclutando

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).

Estado:   Reclutando

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Estado:   Reclutando

A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia

Estado:   Reclutando

Study to Evaluate the Safety of Repatha® in Pregnancy

Estado:   Reclutando

Vascular Inflammation and Cholesterol Lowering Therapy

Estado:   Sin reclutar

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

Estado:   Sin reclutar